{"id":7625,"date":"2026-03-24T08:14:41","date_gmt":"2026-03-24T12:14:41","guid":{"rendered":"https:\/\/cqdm.org\/?p=7625"},"modified":"2026-03-24T08:15:08","modified_gmt":"2026-03-24T12:15:08","slug":"epitopea-success-story","status":"publish","type":"post","link":"https:\/\/cqdm.org\/en\/news-and-events\/epitopea-success-story\/","title":{"rendered":"Epitopea Success Story"},"content":{"rendered":"\n<p><strong>Discover the story of <a href=\"https:\/\/www.epitopea.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Epitopea<\/a>, a biotechnology company specializing in immunotherapy, born from a research project supported by CQDM.<\/strong><\/p>\n\n\n\n<p>Based in Montr\u00e9al and Cambridge (UK), Epitopea is developing next\u2011generation therapeutic vaccines. Their goal: to train the immune system to precisely recognize and target tumor\u2011specific antigens, opening up new possibilities in cancer treatment.<\/p>\n\n\n\n<p>From the earliest stages, CQDM\u2019s strategic support played a decisive role. By backing the project at an early phase, CQDM helped accelerate scientific progress and reach key milestones toward technology validation.<\/p>\n\n\n\n<p>Today, Epitopea is emerging as a promising player in personalized immunotherapy.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/cqdm.org\/en\/achievement\/success-story\/\" target=\"_blank\" rel=\"noreferrer noopener\">Learn More<\/a><\/div>\n\n\n\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/cqdm.org\/wp-content\/uploads\/2026\/03\/Epitopea-Final-Version-EN-1703.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Download the Full Story<\/a><\/div>\n<\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Discover the story of Epitopea, a biotechnology company specializing in immunotherapy, born from a research project supported by CQDM. Based in Montr\u00e9al and Cambridge (UK), Epitopea is developing next\u2011generation therapeutic vaccines. Their goal: to train the immune system to precisely recognize and target tumor\u2011specific antigens, opening up new possibilities in cancer treatment. From the earliest&hellip;<\/p>\n","protected":false},"author":2,"featured_media":7622,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7625","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-our-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/7625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=7625"}],"version-history":[{"count":3,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/7625\/revisions"}],"predecessor-version":[{"id":7630,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/7625\/revisions\/7630"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/7622"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=7625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/categories?post=7625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/tags?post=7625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}